Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Subjects:

Data Sheet 1_Decreased cigarette smoking may partially explain the increased prevalence of antinuclear antibodies in the United States.pdf by Gregg E. Dinse (4500940)

“…</p>Discussion<p>Although smoking causes harmful health effects, ANA data are consistent with smoking playing a role in decreasing autoimmunity. Recent vaping among adolescents may partially explain their large increase in ANA prevalence. …”

Table 1_Effect of decreased suspended sediment content on chlorophyll-a in Dongting Lake, China.docx by Le Zhang (88249)

“…The reduction in SSC may influence chlorophyll-a (Chl-a) concentrations in water, thereby further affecting the aquatic ecological environment. …”

nsP4-C483Y or Q192L mutations decrease sensitivity to 4′-FlU. by Peiqi Yin (6533747)

Table 1_NSAID use may decrease serum Klotho levels.docx by Jingchao Yan (14079168)

“…Objective<p>To validate the hypothesis proposed by previous studies, which suggests that NSAID use may elevate Klotho levels.</p>Method<p>We conducted a cross-sectional study involving 11,626 adults from the National Health and Nutrition Examination Survey (NHANES) 2007-2016. …”

HDECO: A method for Decreasing energy and cost by using virtual machine migration by considering hybrid parameters by Arash GhorbanniaDelavar (22563696)

“…<h2>Summary</h2><p dir="ltr">This research introduces <b>HDECO</b> (Hybrid Decreasing Energy and Cost Optimization) — a method designed to reduce both energy consumption and execution cost in cloud datacenters through intelligent virtual machine migration. …”

Point cloud fusion instance effect. by Hongliang Zou (20707270)

Subjects:

The nsP4-Q192L and C483Y mutations decrease the 4′-FlU sensitivity of both replication and transcription. by Peiqi Yin (6533747)

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects: